Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary aim of the study is to demonstrate that mitochondrial dysfunction occurs in both skeletal muscle and circulating platelets of severely septic and septic shock ICU-admitted patients. Secondary aims are to clarify the pathogenesis and the clinical relevance of mitochondrial damage during sepsis.
| Condition |
|---|
|
Severe Sepsis Septic Shock |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis. |
muscle tissue, platelets, plasma
| Estimated Enrollment: | 50 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | October 2010 |
| Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
The primary aim of the study is to demonstrate that mitochondrial dysfunction occurs in both skeletal muscle and circulating platelets of severely septic and septic shock ICU-admitted patients, as compared to otherwise healthy surgical ones. In order to better clarify the pathogenesis of mitochondrial dysfunction during sepsis, cardiogenic shock patients (suffering from systemic hypoperfusion) will act as additional controls. Markers of oxidative stress will be measured in tissue samples from septic patients. The clinical relevance of mitochondrial dysfunction during sepsis will be assessed in terms of both skeletal muscle and platelet function.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Adult ICU-admitted severely septic and septic shock patientes; adult ICU-admitted cardiogenic shock patients; surgical patients
Inclusion Criteria:
- Consecutive ICU-admitted severely septic or septic shock patients.
Exclusion Criteria:
- Severe thrombocytopenia.
- Severe coagulopathy.
- Pre-existing mitochondrial disease
Contacts and Locations| Contact: Luciano Gattinoni, MD | 0039.02.5503.3232 | gattinon@policlinico.mi.it |
| Contact: Alessandro Protti, MD | 0039.02.5503.3232 | alessandro.protti@policlinico.mi.it |
| Italy | |
| Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena | Recruiting |
| Milan, Italy, 20122 | |
| Contact: Luciano Gattinoni, MD +390255033231 gattinon@policlinico.mi.it | |
| Study Chair: | Luciano Gattinoni, MD | Ospedale Maggiore Policlinico Mangiagalli e Regina Elena |
| Principal Investigator: | Alessandro Protti, MD | Ospedale Maggiore Policlinico Mangiagalli e Regina Elena |
More Information
No publications provided
| Responsible Party: | Luciano Gattinoni, Study Chair, Fondazione Ospedale Maggiore |
| ClinicalTrials.gov Identifier: | NCT00541827 History of Changes |
| Other Study ID Numbers: | assente |
| Study First Received: | October 8, 2007 |
| Last Updated: | February 4, 2010 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico:
|
Sepsis. Shock, septic. Mitochondria. |
Additional relevant MeSH terms:
|
Sepsis Toxemia Shock Shock, Septic |
Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on June 18, 2013